Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug;43(4):450-457.
doi: 10.23736/S0392-9590.24.05266-0. Epub 2024 Sep 20.

Dyslipidemia and lower extremity arterial disease

Kosmas I Paraskevas  1 , Pavel Poredos  2 , Agata Stanek  3 , Ales Blinc  2   4 , Arkadiusz Jawien  5 , Pier Luigi Antignani  6 , Armando Mansilha  7 , Dimitri P Mikhailidis  8   9
Affiliations
Review

Dyslipidemia and lower extremity arterial disease

Kosmas I Paraskevas et al. Int Angiol. 2024 Aug.

Abstract

Introduction: Dyslipidemia is an established risk factor for cardiovascular diseases. We aimed to review its role in the pathogenesis of lower extremity arterial disease (LEAD), as well as the effect of lipid-lowering treatment on the progression of LEAD.

Evidence acquisition: PubMed/MedLine, EMBASE and Scopus were searched between January 1990 and January 2024 for articles investigating the role of dyslipidemias and hyperlipidemias in the pathogenesis of LEAD. A separate search focused on the effects of lipid-lowering therapy on patients with LEAD.

Evidence synthesis: There is evidence that dyslipidemias play a major role in the development of LEAD. All patients with LEAD should receive intensive lipid-lowering therapy for the reduction not only of claudication symptoms and amputation rates, but also of myocardial infarction and cardiovascular event rates.

Conclusions: Vascular specialists should keep in mind the pivotal role of dyslipidemia in the pathogenesis and progression of LEAD.

PubMed Disclaimer

MeSH terms

Substances